Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Generation T-Cell Engager Therapies
Excalipoint Therapeutics, a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases, today announced an oversubscribed $68.7 million seed financing round to support advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programs.
